| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]
|
Meade, Thomas W
|
|
2001
|
2 |
4 |
p. 195-204
|
artikel
|
| 2 |
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
|
Mahaffey, Kenneth W
|
|
2001
|
2 |
4 |
p. 187-194
|
artikel
|
| 3 |
Dose response of ACE inhibitors: implications of the SECURE trial
|
Lonn, Eva
|
|
2001
|
2 |
4 |
p. 155-159
|
artikel
|
| 4 |
How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
|
Bonarjee, Vernon VS
|
|
2001
|
2 |
4 |
p. 151-155
|
artikel
|
| 5 |
Organizing the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): National Institutes of Health, Health Care Financing Administration, and industry funding
|
Hobson, Robert W
|
|
2001
|
2 |
4 |
p. 160-164
|
artikel
|
| 6 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
|
Suwaidi, Jassim Al
|
|
2001
|
2 |
4 |
p. 171-179
|
artikel
|
| 7 |
Systematic adjudication of myocardial infarction end-points in an international clinical trial
|
Mahaffey, Kenneth W
|
|
2001
|
2 |
4 |
p. 180-186
|
artikel
|
| 8 |
The role of dyslipidemia and statins in venous thromboembolism
|
Ray, Joel G
|
|
2001
|
2 |
4 |
p. 165-170
|
artikel
|
Tijdschrift beschrijving